There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
Researchers are attacking six primary diseases: arthritis, osteoporosis, heart disease, stroke, lung cancer and breast cancer.
Arthritis affects 23 million women in the United States, costing the U.S. economy nearly $65 billion each year, according to PhRMA. Pharmaceutical companies are researching 55 new products to treat the condition, including a new class of drugs known as selective COX-2 inhibitors.
Osteoporosis affects one in four women and results in more than 1.3 million hip fractures per year. The Alliance for Aging Research estimates the annual cost of the condition to be $10 million. At least one of 27 new products for osteoporosis has the potential to build bone mass by up to 10%, PhRMA stated.
More than half of American deaths caused by heart disease and stroke occur in women. Although more men suffer strokes, more women die from them, and 44% of women who have heart attacks die, compared with only 27% of men. PhRMA's survey revealed that there are 48 new medicines in the drug pipeline for cardiovascular illness.
But pharmaceutical companies have devoted the greatest research and development energy to finding treatments for breast and lung cancers. Breast cancer affects 8 million American women and costs $10 billion per year. Lung cancer - the leading cause of cancer death among women, according to the American Cancer Society - kills an estimated 66,000 women annually.
PhRMA found that 109 products are being developed to battle breast and lung cancer. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.